We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First Lab-in-a-Briefcase to Boost Global Early Diagnosis of Cancer

By LabMedica International staff writers
Posted on 18 Nov 2015
Image: The 4 main components of the newly developed “lab-in-a-briefcase.” (1) Disposable multiple syringe aspirator (MSA) devices, each of which can perform 10 replicate ELISA tests on each of the 8 samples. (2) Customized microwell plates preloaded with reagents that interface with the MSA. (3) Portable USB-powered film scanner for colorimetric signal quantification. (4) Portable computer for real-time data analysis (Photo courtesy of Barbosa AI et al., 2015, and the journal Lab on a Chip.)
Image: The 4 main components of the newly developed “lab-in-a-briefcase.” (1) Disposable multiple syringe aspirator (MSA) devices, each of which can perform 10 replicate ELISA tests on each of the 8 samples. (2) Customized microwell plates preloaded with reagents that interface with the MSA. (3) Portable USB-powered film scanner for colorimetric signal quantification. (4) Portable computer for real-time data analysis (Photo courtesy of Barbosa AI et al., 2015, and the journal Lab on a Chip.)
To help boost early cancer detection rates worldwide, scientists have developed an all-in-one portable mini-laboratory for point-of-care cancer screening, rapid detection, and monitoring. The prototype successfully tested for prostate cancer, and can operate at even at high temperatures often found in remote areas without air-conditioned clinics.

An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.

One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.

The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.

The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.

A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.

“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said

Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”

The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.

Related Links:

Loughborough University
Capillary Film Technology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hematology Consumables
Bioblood Devices
New
Gold Member
Platelet Function Analyzer
PL-12

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more